Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout

Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), today announced that it has entered into agreements for a comprehensive refinancing transaction, consisting of (i) the repayment in full of the existing European Investment Bank (the " EIB ") loan and the buyback of a portion of the warrants issued in favor of the EIB in connection with the loan (the " EIB Transactions "), (ii) a new debt financing with BlackRock and Claret Capital Partners of up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million (the " Debt Financing Transaction ") with an initial aggregate drawdown of €75 million (corresponding to the drawdown of Tranche A and Tranche B of the Debt Financing), and (iii) an offering in the United States of 27,272,727 new American Depositary Shares (" ADSs "), each representing one new ordinary share of the Company with a nominal value of €0.01 (the " Ordinary Shares "), at an offering price of $4.40 per ADS (the " Equity Offering ", and together with the EIB Transactions and the Debt Financing Transaction, the " Combined Transaction ") 3 .